- Home
- RGC vs STTK Comparison
RGC vs STTK Comparison
Compare RGC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- STTK
- Stock Information
- Founded
- RGC 2014
- STTK 2016
- Country
- RGC Hong Kong
- STTK United States
- Employees
- RGC N/A
- STTK N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- STTK Health Care
- Exchange
- RGC Nasdaq
- STTK Nasdaq
- Market Cap
- RGC 171.1M
- STTK 173.6M
- IPO Year
- RGC 2021
- STTK 2020
- Fundamental
- Price
- RGC $5.87
- STTK $3.64
- Analyst Decision
- RGC
- STTK Strong Buy
- Analyst Count
- RGC 0
- STTK 3
- Target Price
- RGC N/A
- STTK $10.67
- AVG Volume (30 Days)
- RGC 109.9K
- STTK 152.9K
- Earning Date
- RGC 10-25-2024
- STTK 11-07-2024
- Dividend Yield
- RGC N/A
- STTK N/A
- EPS Growth
- RGC N/A
- STTK N/A
- EPS
- RGC N/A
- STTK N/A
- Revenue
- RGC N/A
- STTK $4,123,999.00
- Revenue This Year
- RGC N/A
- STTK $164.45
- Revenue Next Year
- RGC N/A
- STTK N/A
- P/E Ratio
- RGC N/A
- STTK N/A
- Revenue Growth
- RGC N/A
- STTK 380.09
- 52 Week Low
- RGC $3.03
- STTK $1.33
- 52 Week High
- RGC $32.44
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- RGC 40.75
- STTK 51.46
- Support Level
- RGC $6.55
- STTK $3.37
- Resistance Level
- RGC $8.67
- STTK $3.75
- Average True Range (ATR)
- RGC 0.86
- STTK 0.23
- MACD
- RGC -0.31
- STTK 0.07
- Stochastic Oscillator
- RGC 9.38
- STTK 78.85
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.